Clinical trials: Urinary Complications
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
Urinary Tract Infections
A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)
The study will be conducted to evaluate the therapeutic response (combined per participant microbiological and clinical response) of oral gepotidacin compared to oral nitrofurantoin for treatment of uncomplicated UTI (acute…
- Trial name
- NCT04020341
- Testing
- Gepotidacin, Nitrofurantoin
- Where
- 103 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,531 people
- Sponsor
- GlaxoSmithKline
Metastatic Urothelial Carcinoma, Urothelial Cancer
A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different Histologies
Bladder cancer (urothelial carcinoma) is a disease where cells in the bladder grow out of control. The bladder is an organ in the lower part of the body that stores urine.
- Conditions
- Metastatic Urothelial Carcinoma, Urothelial Cancer, Urothelial Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma
- Trial name
- NCT07897669
- Volunteers
- 5,122 people
- Sponsor
- Pfizer
Multiple Sclerosis, Neurogenic Bladder
Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis
A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder symptoms due to spinal cord injury or multiple sclerosis
- Conditions
- Multiple Sclerosis, Neurogenic Bladder, Spinal Cord Diseases
- Trial name
- SONIC (NCT00629642)
- Testing
- Solifenacin Succinate, Oxybutynin Hydrochloride
- Where
- 39 sites in Australia, Belgium and 9 more
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
This Phase 3 trial will investigate the efficacy, tolerability and safety of fesoterodine fumarate (SR) (fesoterodine; SPM 907) in adult male and female subjects with overactive bladder syndrome.
- Trial name
- NCT00138723
- Testing
- SPM 907
- Sponsor
- Pfizer
Non-muscle Invasive Bladder Cancer (NMIBC)
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
This is an open-label, phase 2, randomized study of intravesical N-803 plus BCG (experimental arm A) and intravesical N-803 plus gemcitabine (experimental arm B) in participants who have intermediate-risk Ta/T1 papillary disease.
- Trial name
- NCT06829823
- Testing
- N-803 and BCG, N-803 and Gemcitabine
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.
Urinary Tract Infection
Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections
This trial evaluated how effective and safe Cipro XR was in treating female patients with signs and symptoms of a lower urinary tract infections.
- Trial name
- NCT00669994
- Testing
- Ciprofloxacin
- Where
- 31 sites in United States
- Volunteers
- 180 people
- Sponsor
- Bayer
Stress Urinary Incontinence, Vulvovaginal Signs and Symptoms
Clinical Evaluation of Fractional Bi-Polar RF for Symptoms of SUI and Vulvovaginal Atrophy
Clinical Evaluation of Fractional Bi-Polar Radio-Frequency for Symptoms of Stress Urinary Incontinence and Vulvovaginal Atrophy
- Trial name
- NCT04705571
- Testing
- MorpheusV Applicator
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- InMode MD Ltd.
Urinary Incontinence, Stress
Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP® Tape)
Validation of a new Quality of Life (QoL) questionnaire in a population of patient gaining a TiLOOP® TAPE surgical mesh for stabilization of the urethra.
- Trial name
- NCT01358214
- Testing
- Questionnaire on Quality of Life.
- Where
- Germany
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- pfm medical gmbh
Bladder Cancer
A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)
This is a Phase 1, multicenter, open-label study of intravesical Toca 511 followed by oral Toca FC in patients with high grade (HG) non-muscle invasive bladder cancer (NMIBC), with cohort expansion at the recommended Phase 2…
- Trial name
- NCT04089163
- Testing
- Toca 511, Toca FC (extended-release formulation of flucytosine)
- Sponsor
- Tocagen Inc.
Benign Prostatic Hyperplasia, BPH
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207…
- Conditions
- Benign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS), LUTS
- Trial name
- NCT01846793
- Testing
- NX-1207
- Where
- 17 sites in United States
- Volunteers
- 160 people
- Sponsor
- Nymox Corporation
Urinary Disorders, Urinary Incontinence
Study Evaluating the Ability of a NIRS Module to Detect a Urodynamic Variation in Humans (DETTECH)
NIRS technology is therefore a technique that exploits the different absorption properties of oxygenated and deoxygenated hemoglobin to evaluate the degree of tissue oxygenation.
- Conditions
- Urinary Disorders, Urinary Incontinence, Urinary Bladder Diseases
- Trial name
- DETTECH (NCT04161716)
- Testing
- NIRS recording
- Where
- France
- Volunteers
- 40 people
- Sponsor
- BioSerenity
Lung Cancer, Head and Neck Cancer
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
- Conditions
- Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer
- Trial name
- DELFI-L101 (NCT04825834)
- Testing
- Blood Sample Collection
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 2,992 people
- Sponsor
- Delfi Diagnostics Inc.
Bladder Cancer
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of PF-07225570 alone or in combination with an anti-PD-1 antibody in participants with recurrent…
- Trial name
- NCT05259397
- Testing
- PF-07225570, sasanlimab
- Where
- 4 sites in United States, Poland
- Sponsor
- Pfizer
Cystinuria
This Study Evaluates the Superiority of Daily Self-pH Monitorization of Lit-control®pH Meter Compared to the Monitorization of Reactive Strips (Standard of Care).
This study evaluates the superiority of daily self-pH monitorization of Lit-control®pH meter compared to the monitorization of reactive strips (standard of care).
- Trial name
- NCT03539926
- Testing
- Lit-control®pH Meter, Reactive strips
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Devicare S.L.
Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients
This is a phase Ib, open-label, single-arm, single-center study conducted in Canada. Subjects with NMIBC (Ta, T1, and/or Tis) who are not candidates for or have refused radical cystectomy will be eligible for participation in the…
- Trial name
- NCT03053635
- Testing
- TLD1433 infusion and photodynamic therapy (PDT) treatment
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Theralase® Technologies Inc.
Bladder Pain Syndrome, Interstitial Cystitis
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
The purpose of this study is to investigate efficacy, safety and tolerability of ASP6294 in female participants with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC).
- Trial name
- SERENITY (NCT03282318)
- Testing
- ASP6294
- Where
- 28 sites in Belgium, Czechia and 8 more
- Volunteers
- 119 people
- Sponsor
- Astellas Pharma Europe B.V.
Urinary Retention
A Confirmatory Study Confirming Performance of a New Intermittent Catheter
A multi-centre, randomized, controlled crossover design. The total study duration for the individual subject was approximately 9 weeks.
- Trial name
- NCT05485935
- Testing
- Investigational device - intermittent catheter with micro-hole zone, Comparator - standard intermittent catheter
- Where
- 6 sites in Denmark, France and 2 more
- Volunteers
- 73 people
- Sponsor
- Coloplast A/S
Urinary Lithiasis
Evaluation of the Safety and Performance of the Hydrustent® Biodegradable Hydrogel Ureteral Stent
The goal of this clinical investigation is to evaluate whether the Hydrustent® medical device is safe and if maintain the urinary flow inside the ureter in adults.
- Trial name
- Hydrustent (NCT06719089)
- Testing
- Biodegradable double loop ureteral stent, PolyUrethane Double Loop Ureteral Stent
- Where
- 4 sites in Portugal
- Volunteers
- 134 people
- Sponsor
- Hydrumedical
Overactive Bladder
Evaluation of the Tensi+ Device for the Treatment of Overactive Bladder
Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management.
- Trial name
- NCT06847789
- Testing
- Tensi+
- Where
- France
- Volunteers
- 79 people
- Sponsor
- Stimuli Technology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.